文献速递临床微生物分子诊断

多重PCR系统直接从阳性血培养肉汤中快速检测革兰阴性菌耐药决定因子

Rapid detection of gram-negative antimicrobial resistance determinants directly from positive blood culture broths using a multiplex PCR system.
PubMed 文献 · J Clin Microbiol · 2025-10-21

本研究前瞻性评估原型BIOFIRE FILMARRAY抗菌药物耐药(AMR)Panel(检测31个AMR基因的快速多重PCR)在148例革兰阴性菌血症患者阳性血培养肉汤上的性能,并与肉汤微量稀释法比较。结果显示,对大肠埃希菌和肺炎克雷伯菌,该Panel预测耐药性的敏感性在多数药物中≥90%,特异性也高;模拟管理研究提示可更早升阶梯或降阶梯β-内酰胺治疗。其他目标菌性能欠佳。

要点

  • 对大肠埃希菌,AMR Panel预测耐药性的敏感性在14种药物中的10种≥90%。
  • 对肺炎克雷伯菌,预测耐药性的敏感性在16种药物中的10种≥90%。
  • 对大肠埃希菌或肺炎克雷伯菌菌血症,该Panel可能使多数患者更早调整β-内酰胺治疗。

核心结论

  • 该多重PCR Panel可快速预测大肠埃希菌和肺炎克雷伯菌菌血症患者对一线抗菌药物的耐药性。
  • 对其他目标革兰阴性菌的性能较差。

研究设计与样本

  • 前瞻性评估原型BIOFIRE FILMARRAY AMR Panel,一种检测31个AMR基因的快速多重PCR。
  • 留取纽约市一家医院148例革兰阴性菌血症患者的阳性血培养肉汤进行检测。
  • 将AMR Panel预测的耐药性与血分离株的肉汤微量稀释法结果比较。
  • 进行模拟管理研究,评估若AMR Panel结果可实时用于患者护理时的治疗优化机会。

主要发现

  • 共纳入148例患者:大肠埃希菌75例、肺炎克雷伯菌44例、铜绿假单胞菌17例、阴沟肠杆菌复合群9例、鲍曼不动杆菌3例。
  • 对大肠埃希菌,AMR Panel预测耐药性的敏感性在14种药物中的10种≥90%,特异性在17种药物中的15种≥90%。
  • 对肺炎克雷伯菌,敏感性在16种药物中的10种≥90%,特异性在所有16种药物中≥90%。
  • 对其他目标菌性能较差。
  • 对大肠埃希菌或肺炎克雷伯菌菌血症,与实际情况相比,使用AMR Panel可能使多数患者更早升阶梯或降阶梯β-内酰胺治疗。

临床怎么用

  • 对阳性血培养肉汤直接检测,约1小时可获得31个AMR基因结果,辅助快速预测大肠埃希菌和肺炎克雷伯菌对β-内酰胺类、氟喹诺酮类和氨基糖苷类的耐药性。
  • 结果可用于更早优化大肠埃希菌或肺炎克雷伯菌菌血症患者的β-内酰胺治疗。

局限性

  • 对其他目标革兰阴性菌(铜绿假单胞菌、阴沟肠杆菌复合群、鲍曼不动杆菌)性能较差。
  • 研究为原型Panel评估,模拟管理研究而非实时干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently available rapid blood culture diagnostics detect few gram-negative resistance determinants, limiting their clinical utility. We prospectively evaluated the prototype BIOFIRE FILMARRAY Antimicrobial Resistance (AMR) Panel, a rapid multiplex PCR test that detects 31 AMR genes, on residual positive blood culture broths from patients with gram-negative bacteremia due to five target organisms at a New York City hospital. Predicted antimicrobial resistance based on the AMR Panel was compared to results from broth microdilution testing of bloodstream isolates recovered in culture. A simulated stewardship study assessed opportunities for the optimization of therapy if the AMR Panel results had been available for patient care in real time. We enrolled 148 patients with gram-negative bacteremia (Escherichia coli, n = 75; Klebsiella pneumoniae, n = 44; Pseudomonas aeruginosa, n = 17; Enterobacter cloacae complex, n = 9; and Acinetobacter baumannii, n = 3). The sensitivity of the AMR Panel for predicting antimicrobial resistance was ≥90% for 10/14 antimicrobial agents in E. coli and for 10/16 agents in K. pneumoniae. Specificity was ≥90% for 15/17 agents in E. coli and for all 16 agents in K. pneumoniae. Performance for other organisms was poor. For E. coli or K. pneumoniae bacteremia, use of the AMR Panel could have led to earlier escalation or de-escalation of β-lactam therapy in a majority of patients compared to what actually occurred. This study demonstrates that a rapid multiplex PCR test with a large menu of AMR genes can be applied to positive blood culture broths to rapidly predict resistance to frontline antimicrobial agents in patients with E. coli or K. pneumoniae bacteremia.IMPORTANCEPatients with gram-negative bacteremia require urgent treatment with antimicrobial agents that are effective against their infecting pathogen. However, conventional laboratory work-up of blood cultures takes days to yield results, and during this time, patients may receive ineffective therapies. We evaluated the prototype BIOFIRE FILMARRAY AMR Panel, an assay that detects 31 genes in gram-negative bacteria that confer resistance to β-lactams, fluoroquinolones, and aminoglycosides in approximately 1 hour, directly from positive blood culture broths, and compared these results to antimicrobial susceptibility testing of isolates recovered in culture. We found that the AMR Panel accurately predicted resistance in Escherichia coli and Klebsiella pneumoniae to most antimicrobials. Moreover, if results from this assay had been used for patient care, there would have been opportunities to optimize antimicrobial prescribing more quickly than using conventional methods. These data demonstrate how novel molecular assays could optimize care for patients with E. coli and K. pneumoniae bacteremia.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Marxreiter S, Marino J, Callan K, et al. Rapid detection of gram-negative antimicrobial resistance determinants directly from positive blood culture broths using a multiplex PCR system. J Clin Microbiol. 2025. PMID: 41117625. doi:10.1128/jcm.00384-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。